Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Dare Bioscience received$0.22 Mil more from issuing new shares than it paid to buy back shares.
It spent$0.20 Mil paying down its debt.
It paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
It received$0.00 Mil from paying cash dividends to shareholders.
It spent$0.00 Mil on other financial activities.
In all, Dare Bioscienceearned$0.01 Mil on financial activities for the
three
months ended in Mar. 2024.
Dare Bioscience Cash Flow from Financing Historical Data
The historical data trend for Dare Bioscience's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Dare Bioscience's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $14.35 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dare Bioscience (NAS:DARE) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Dare Bioscience's issuance of stock for the
three
months ended in Mar. 2024 was $0.22 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Dare Bioscience's repurchase of stock for the
three
months ended in Mar. 2024 was $0.00 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Dare Bioscience's net issuance of debt for the
three
months ended in Mar. 2024 was $-0.20 Mil.
Dare Bioscience spent$0.20 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Dare Bioscience's net issuance of preferred for the
three
months ended in Mar. 2024 was $0.00 Mil.
Dare Bioscience paid$0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Dare Bioscience's cash flow for dividends for the
three
months ended in Mar. 2024 was $0.00 Mil.
Dare Bioscience received$0.00 Mil from paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Dare Bioscience's other financing for the
three
months ended in Mar. 2024 was $-0.00 Mil.
Dare Bioscience spent$0.00 Mil on other financial activities.
Dare Bioscience Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Dare Bioscience's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Dare Bioscience (Dare Bioscience) Business Description
Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DARE has been successfully added to your 